Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O15266
UPID:
SHOX_HUMAN
Alternative names:
Pseudoautosomal homeobox-containing osteogenic protein; Short stature homeobox-containing protein
Alternative UPACC:
O15266; O00412; O00413; O15267
Background:
The Short stature homeobox protein, also known as Pseudoautosomal homeobox-containing osteogenic protein, plays a pivotal role in growth and development. Its alternative name, Short stature homeobox-containing protein, underscores its significance in stature determination.
Therapeutic significance:
Linked to Leri-Weill dyschondrosteosis, Langer mesomelic dysplasia, and idiopathic short stature, X-linked, this protein's understanding could pave the way for innovative treatments for these skeletal dysplasias.